AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with drug-resistant TBView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Evaluating hepatotoxicity of bedaquiline treatment in multi-drug resistant tuberculosis patientsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019An assessment of the effects of dolutegravir on gene expression and levonorgestrel clearance in human hepatocytes in vitroView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Cobicistat (COBI)-boosted Protease Inhibitors (PIs) plasma and intracellular (IC) pharmacokinetics (PK) in nicotine usersView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Glecaprevir/pibrentasvir pharmacokinetics in HCV/HIV patients co-administered with antiretroviral drugsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019The valproic acid – dolutegravir drug-drug interaction is based on displacement of protein binding and unlikely to be clinically relevantView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Valproic acid co-administration is not associated with lower non-dolutegravir antiretrovirals’ exposuresView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Short-term intravenous proton pump inhibitors and histamine H2 antagonists do not negatively affect sustained virologic response in hepatitis C cirrhotic patients treated with ledipasvir or velpatasvir containing antiviral regimens: a case seriesView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019High incidence of drug-drug interactions with hepatitis C direct-acting antivirals in patients hospitalized during their treatmentView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Effect of tenofovir and bacavir on dolutegravir transport in vitro and in vivoView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Comparison of relative bioavailability of pediatric triumeq and pediatric dolutegravir/lamivudine dispersible tablets to conventional film coated tablets in healthy adultsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Influence of SLCO1B1 polymorphisms on lopinavir plasma concentration in Serbian HIV/AIDS patientsView Abstract
